Björklund Pharma

  • Home
  • Company
  • Science & Innovation
  • Publications
  • Media
  • Contact
    • Contact Form

Science & Innovation

Björklund Pharma is an early-stage biopharmaceutical company with product candidates within the following therapeutic areas:

  • Psychiatry
  • Neurology
  • Pain
  • Sleep
  • Dermatology
  • Ophthalmology
  • Cardiology
  • Gastrointestinal
  • Immunology
  • Infectious diseases
  • Bone metabolism
  • Toxicology
  • Pulmonology/respiratory
  • Renal/hepatic
  • Nutraceuticals

Most of the company’s product candidates are in an early preclinical stage. During the preclinical phase, various tests and experiments will be conducted to determine drugs’ safety, effectiveness, and how they are metabolized in the body. This information will be used to design and plan clinical trials to test the drugs on human subjects.

Recent Posts

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment
  • Email
  • Facebook
  • Google+
  • LinkedIn
  • Twitter
  • YouTube

RSS CONEM News

  • DAJTEMU
  • Better Brain Health – We Are What We Eat
  • Zinc, Copper, and Autism Spectrum Disorder
  • Nutritional Minerals and the Periodic Table
  • Semey Revisited: The legacy of nuclear testing in Kazakhstan

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2023 Björklund Pharma AS